resiquimod has been researched along with Liver Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belt, BA; Garrett-Larsen, J; Gerber, SA; Han, BJ; Johnston, CJ; Linehan, DC; Lord, EM; Mills, BN; Murphy, JD; Qin, SS; Uccello, TP; Vrooman, TG; Ye, J | 1 |
| Bie, N; Chen, X; Gan, L; Li, J; Li, S; Li, X; Liu, H; Wei, Z; Xu, H; Yan, Y; Yang, X; Yong, T; Zhang, B; Zhang, X | 1 |
2 other study(ies) available for resiquimod and Liver Neoplasms
| Article | Year |
|---|---|
Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
Topics: Adjuvants, Immunologic; Animals; Antigens, Neoplasm; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Disease Models, Animal; Humans; Imidazoles; Liver Neoplasms; Mice; Pancreatic Neoplasms; Radiosurgery; Toll-Like Receptor 7; Toll-Like Receptor 8; Tumor Microenvironment | 2022 |
Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8
Topics: alpha-Fetoproteins; Animals; Antigens, Neoplasm; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Immunosuppressive Agents; Liver Neoplasms; Male; Mice; Tumor Microenvironment; Tumor-Associated Macrophages | 2023 |